Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$75.96 USD

75.96
649,382

-0.46 (-0.60%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $75.96 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Techne (TECH) Lags Q2 Earnings and Revenue Estimates

Techne (TECH) delivered earnings and revenue surprises of -5.26% and -3.50%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GILD vs. TECH: Which Stock Should Value Investors Buy Now?

GILD vs. TECH: Which Stock Is the Better Value Option?

CELG vs. TECH: Which Stock Is the Better Value Option?

CELG vs. TECH: Which Stock Is the Better Value Option?

Techne (TECH) Q1 Earnings Lag Estimates

Techne (TECH) delivered earnings and revenue surprises of -0.93% and 1.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for August 15th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Techne (TECH) Q4 Earnings and Revenues Lag Estimates

Techne (TECH) delivered earnings and revenue surprises of -4.58% and -3.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?

Within the Health Care Benefits segment, CVS Health (CVS) expects the government programs to go from strength to strength on the back of Medicare growth and major Medicaid wins.

What's in Store for Cardinal Health (CAH) in Q4 Earnings?

Better-than-expected performance at Pharmaceutical and Medical segments are likely to aid Cardinal Health's (CAH) in Q4 earnings.

Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?

Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.

Can Patient Wins Aid GW Pharmaceuticals (GWPH) Q2 Earnings?

GW Pharmaceuticals (GWPH) is witnessing a solid new patient recruitment for Epidolex and a huge number of physicians are recommending the same in their prescriptions.

Can Bruker (BRKR) Q2 Earnings See BioSpin's Growth Revival?

Bruker (BRKR) expects BioSpin to bode well for better organic growth in Q2.

CBM or TECH: Which Is the Better Value Stock Right Now?

CBM vs. TECH: Which Stock Is the Better Value Option?

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Why the Earnings Surprise Streak Could Continue for Techne (TECH)

Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

Myriad Genetics Announces Study Results Of myRisk Cancer Test

The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

Zachary Stutler headshot

5 Biotech Stocks to Buy Right Now

here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.

CBM vs. TECH: Which Stock Is the Better Value Option?

CBM vs. TECH: Which Stock Is the Better Value Option?

Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

Bio-Techne (TECH) sees increase in revenues across key segments.

Techne (TECH) Q2 Earnings and Revenues Surpass Estimates

Techne (TECH) delivered earnings and revenue surprises of 6.00% and 2.57%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.